Zhengzhi Liu

发表

A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif^® in healthy Chinese subjects

Xin-Ning Qu, Lixiu Zhang, Ying Wang, 2022, Journal of Cancer Research and Clinical Oncology.

A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjects

Xin-Ning Qu, Tianying Chang, Q. Ren, 2022, Expert opinion on investigational drugs.

A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects.

Yicheng Zhao, Xin-Ning Qu, Jing Lan, 2022, International immunopharmacology.

A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects

Yicheng Zhao, Zeyu Wang, Lixiu Zhang, 2022, Expert opinion on drug metabolism & toxicology.

Pharmacokinetics and safety of the two oral cefaclor formulations in healthy chinese subjects in the fasting and postprandial states

Xin-Ning Qu, Peng Li, Q. Ren, 2022, Frontiers in Pharmacology.

A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects

Yanli Wang, Zeyu Wang, Xin-Ning Qu, 2021, Expert opinion on biological therapy.

Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers

Xinran Ren, Yicheng Zhao, Yanli Wang, 2021, Frontiers in Pharmacology.

Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions

Tianying Chang, Q. Ren, Jinling Xue, 2022, Investigational New Drugs.

Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial

Xin-Ning Qu, Xiuge Wang, Tianying Chang, 2023, Expert review of clinical pharmacology.

Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects

Q. Ren, Yingzi Cui, Guang-ping Liu, 2023, Expert opinion on investigational drugs.

Bioequivalence of two esomeprazole magnesium enteric-coated formulations in healthy Chinese subjects

Q. Ren, Zhengzhi Liu, Yannan Zhou, 2020, World journal of clinical cases.

A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers

Xinran Ren, Yanli Wang, Xin-Ning Qu, 2021, Expert opinion on biological therapy.

A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar

Jinling Xue, Yanli Wang, Zhengzhi Liu, 2023, Expert opinion on drug metabolism & toxicology.